What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
The scientist’s investigation covers issues in Internal medicine, Surgery, Sarcoma, Oncology and Pathology.
His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology.
His work is dedicated to discovering how Surgery, Clinical trial are connected with Discontinuation and other disciplines.
His Sarcoma research is multidisciplinary, incorporating elements of Soft tissue, Cancer research, Prospective cohort study and Leiomyosarcoma.
In his study, which falls under the umbrella issue of Oncology, Renal cell carcinoma is strongly linked to Carcinoma.
His Pathology research incorporates themes from Biomarker, Targeted therapy and Interleukin 10.
His most cited work include:
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial* (1359 citations)
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial (1193 citations)
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (972 citations)
What are the main themes of his work throughout his whole career to date?
Jean-Yves Blay spends much of his time researching Internal medicine, Oncology, Sarcoma, Surgery and Cancer.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Soft tissue sarcoma.
Jean-Yves Blay works mostly in the field of Oncology, limiting it down to topics relating to Placebo and, in certain cases, Regorafenib.
His Sarcoma study incorporates themes from Cancer research, Incidence, Soft tissue and Leiomyosarcoma.
His study connects Hazard ratio and Surgery.
The Cancer study combines topics in areas such as Immunology and Family medicine.
He most often published in these fields:
- Internal medicine (51.78%)
- Oncology (33.22%)
- Sarcoma (27.26%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (51.78%)
- Sarcoma (27.26%)
- Oncology (33.22%)
In recent papers he was focusing on the following fields of study:
Jean-Yves Blay mainly focuses on Internal medicine, Sarcoma, Oncology, Cancer research and Soft tissue sarcoma.
His Cancer, Clinical trial and Clinical endpoint study in the realm of Internal medicine connects with subjects such as In patient.
His Sarcoma study combines topics from a wide range of disciplines, such as Retrospective cohort study, Incidence, Chemotherapy and Hazard ratio.
His studies in Hazard ratio integrate themes in fields like Surgery, Proportional hazards model and Leiomyosarcoma.
His work carried out in the field of Oncology brings together such families of science as Gemcitabine, GiST, Phases of clinical research and Doxorubicin.
He has researched Cancer research in several fields, including Immune checkpoint, Immunohistochemistry, Carcinogenesis, Gene and Immune system.
Between 2017 and 2021, his most popular works were:
- Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† (739 citations)
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (173 citations)
- Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (137 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Sarcoma, Oncology, Clinical endpoint and Clinical trial.
As part of his studies on Internal medicine, Jean-Yves Blay often connects relevant areas like Soft tissue sarcoma.
His Sarcoma research incorporates themes from Gastroenterology, Radiation therapy, Retrospective cohort study and Hazard ratio.
His research in Oncology intersects with topics in Gemcitabine, Chemotherapy, Doxorubicin, Anthracycline and Leiomyosarcoma.
His study in Clinical endpoint is interdisciplinary in nature, drawing from both Placebo, Adverse effect, Phases of clinical research and Performance status.
While the research belongs to areas of Clinical trial, Jean-Yves Blay spends his time largely on the problem of Survival rate, intersecting his research to questions surrounding Prospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
